Table 2.

Cox proportional hazards model for PFS with MRD durability status as a covariate

Variable	MRD negativity sustained vs not sustained for ≥6 mo		MRD negativity sustained vs not sustained for ≥12 mo
		HR (95% CI)	P	HR (95% CI)	P
Univariate analysis
Sustained MRD negativity (10−5)	0.10 (0.06-0.18)	<.0001	0.09 (0.05-0.17)	<.0001
Multivariate analysis 1
Sustained MRD negativity (10−5)	0.12 (0.07-0.20)	<.0001	0.11 (0.05-0.21)	<.0001
Treatment (daratumumab-containing regimen vs SoC)	0.55 (0.48-0.64)	<.0001	0.55 (0.47-0.64)	<.0001
Multivariate analysis 2
Sustained MRD negativity (10−5)	0.11 (0.07-0.19)	<.0001	0.10 (0.05-0.20)	<.0001
Treatment (daratumumab-containing regimen vs SoC)	0.54 (0.47-0.63)	<.0001	0.54 (0.47-0.63)	<.0001
Age (<75 vs ≥75 y)	0.99 (0.85-1.15)	.8471	1.01 (0.87-1.17)	.9171
ISS disease stage (I vs III)	0.46 (0.38-0.57)	<.0001	0.48 (0.39-0.59)	<.0001
ISS disease stage (II vs III)	0.82 (0.70-0.96)	.0166	0.82 (0.70-0.97)	.0178
Region (other vs NA/EU)	0.72 (0.62-0.83)	<.0001	0.72 (0.62-0.84)	<.0001

NA/EU, North America/Europe; SoC, standard of care.

Data are for a univariate and multivariate analysis of combined data from the MAIA and ALCYONE studies among patients who did and did not achieve sustained MRD negativity lasting ≥6 months or patients who did and did not achieve sustained MRD negativity lasting ≥12 months. The following variables were evaluated: sustained MRD negativity, treatment group, age, ISS disease stage, and region.